Pleurovenous Shunt Placement for the Management of Nonmalignant Pleural Effusion

Abstract

Therapeutic thoracentesis is a first-line therapy in the management of patients with medically refractory, nonmalignant pleural effusion. However, when required in short intervals, serial thoracenteses can lead to increased procedure-related complications and negatively impact quality of life. Alternative treatment options vary depending on the etiology of fluid accumulation. Hepatic hydrothorax secondary to cirrhosis is a common cause of medically refractory pleural effusion encountered by interventional radiologists. In select patients in whom surgical pleurodesis, transjugular intrahepatic portosystemic shunt placement, and/or tunneled pleural catheter placement cannot be performed or provide inadequate relief, implantation of a pleurovenous (Denver) shunt may assist in palliation. The Denver shunt system allows decompression of pleural fluid into the central venous circulation by utilizing unidirectional valves and a manually operated subcutaneous pump. Though limited reports have described favorable technical and clinical success, more research is required to determine the safety and efficacy of this procedure. This article discusses pleurovenous shunt placement, postprocedure shunt evaluation, and potential associated complications.

Keywords

Denver shunt - pleurovenous shunt - hepatic hydrothorax - nonmalignant pleural effusion - interventional radiology

Publication History

Article published online:
31 August 2022

• References

• 1 Leveen HH, Christoudias G, Ip M, Luft R, Falk G, Grosberg S. Peritoneo-venous shunting for ascites. Ann Surg 1974; 180 (04) 580-591
• 2 Oosterlee J. Peritoneovenous shunting for ascites in cancer patients. Br J Surg 1980; 67 (09) 663-666
• 3 CareFusion Corporation. Denver ascites shunts for patients with refractory ascites. 2012 product brochure. . Accessed September 13, 2021 at: https://www.bd.com/en-in/our-products/interventional-procedures/drainage/denver-shunts
• 4 Light RW. Pleural diseases. Dis Mon 1992; 38 (05) 266-331
• 5 Walker SP, Morley AJ, Stadon L. et al. Nonmalignant pleural effusions: a prospective study of 265 consecutive unselected patients. Chest 2017; 151 (05) 1099-1105
• 6 Milanez de Campos JR, Andrade Filho LO, de Campos Werebe E, Pandulo FL, Filomeno LT, Jatene FB. Hepatic hydrothorax. Semin Respir Crit Care Med 2001; 22 (06) 665-674
• 7 Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: a systematic review and cumulative meta-analysis. World J Hepatol 2015; 7 (13) 1797-1806
• 8 Falchuk KR, Jacoby I, Colucci WS, Rybak ME. Tetracycline-induced pleural symphysis for recurrent hydrothorax complicating cirrhosis. A new approach to treatment. Gastroenterology 1977; 72 (02) 319-321
• 9 Huang PM, Kuo SW, Lee JM. Thoracoscopic diaphragmatic repair for refractory hepatic hydrothorax: application of pleural flap and mesh onlay reinforcement. Thorac Cardiovasc Surg 2006; 54 (01) 47-50
• 10 Alba D, Molina F, Ripoll MM, Castillo P, Lizasoain J, Vázquez JJ. [Pleuroperitoneal shunt in the treatment of pleural effusion associated with cirrhosis]. Med Interna 1993; 10 (12) 604-606
• 11 Iyer NP, Reddy CB, Wahidi MM. et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta-analysis. Ann Am Thorac Soc 2019; 16 (01) 124-131
• 12 Bhatnagar R, Reid ED, Corcoran JP. et al. Indwelling pleural catheters for non-malignant effusions: a multicentre review of practice. Thorax 2014; 69 (10) 959-961
• 13 Chalhoub M, Harris K, Castellano M, Maroun R, Bourjeily G. The use of the PleurX catheter in the management of non-malignant pleural effusions. Chron Respir Dis 2011; 8 (03) 185-191
• 14 Martin LG. Percutaneous placement and management of peritoneovenous shunts. Semin Intervent Radiol 2012; 29 (02) 129-134
• 15 Orsi F, Grasso RF, Bonomo G, Monti C, Marinucci I, Bellomi M. Percutaneous peritoneovenous shunt positioning: technique and preliminary results. Eur Radiol 2002; 12 (05) 1188-1192
• 16 White MA, Agle SC, Padia RK, Zervos EE. Denver peritoneovenous shunts for the management of malignant ascites: a review of the literature in the post LeVeen Era. Am Surg 2011; 77 (08) 1070-1075
• 17 Oizumi H, Inui K, Tatebe S, Ishihara R, Washio M. [A case of intractable hepatic hydrothorax treated by pleuro-venous shunt]. Nihon Kyobu Geka Gakkai Zasshi 1989; 37 (04) 751-754
• 18 Artemiou O, Marta GM, Klepetko W, Wolner E, Müller MR. Pleurovenous shunting in the treatment of nonmalignant pleural effusion. Ann Thorac Surg 2003; 76 (01) 231-233
• 19 Bayram AS, Köprücüoğlu M, Aygün M, Gebitekin C. Pleurovenous shunt for treating refractory benign pleural effusion. Eur J Cardiothorac Surg 2008; 33 (05) 942-943
• 20 Hadsaitong D, Suttithawil W. Pleurovenous shunt in treating refractory nonmalignant hepatic hydrothorax: a case report. Respir Med 2005; 99 (12) 1603-1605
• 21 Segawa T, Kato K, Kawashima K, Suzuki T, Ehara S. The influence of a peritoneovenous shunt for cirrhotic and malignant intractable ascites on renal function. Acta Radiol Open 2018; 7 (03) 2058460118764208
• 22 Bernhoft RA, Pellegrini CA, Way LW. Peritoneovenous shunt for refractory ascites: operative complications and long-term results. Arch Surg 1982; 117 (05) 631-635
• 23 Reinhold RB, Lokich JJ, Tomashefski J, Costello P. Management of malignant ascites with peritoneovenous shunting. Am J Surg 1983; 145 (04) 455-457